Drug-Resistant Falciparum Malaria among the Mayongong Indians in the Brazilian Amazon *

Ferraroni, José João; Hayes, Jack

doi:10.4269/ajtmh.1979.28.909

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 74 , 75 The combination of sulfa drugs and pyrimethamine proved to be potent in the laboratory, as well as in the field against chloroquine-resistant uncomplicated malaria but, again, resistance appeared rapidly in the Asia Pacific regions in the late 1970s, as well as in South America. 76 – 79 …”

Section: Antimalarial Drug Resistancementioning

confidence: 99%

Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network

Cui¹,

Mharakurwa

Ndiaye³

et al. 2015

The American Journal of Tropical Medicine and Hygiene

266

223

View full text Add to dashboard Cite

Antimalarial drugs are key tools for the control and elimination of malaria. Recent decreases in the global malaria burden are likely due, in part, to the deployment of artemisinin-based combination therapies. Therefore, the emergence and potential spread of artemisinin-resistant parasites in southeast Asia and changes in sensitivities to artemisinin partner drugs have raised concerns. In recognition of this urgent threat, the International Centers of Excellence for Malaria Research (ICEMRs) are closely monitoring antimalarial drug efficacy and studying the mechanisms underlying drug resistance. At multiple sentinel sites of the global ICEMR network, research activities include clinical studies to track the efficacies of antimalarial drugs, ex vivo/in vitro assays to measure drug susceptibilities of parasite isolates, and characterization of resistance-mediating parasite polymorphisms. Taken together, these efforts offer an increasingly comprehensive assessment of the efficacies of antimalarial therapies, and enable us to predict the emergence of drug resistance and to guide local antimalarial drug policies. Here we briefly review worldwide antimalarial drug resistance concerns, summarize research activities of the ICEMRs related to drug resistance, and assess the global impacts of the ICEMR programs.

show abstract

Section: Antimalarial Drug Resistancementioning

confidence: 99%

Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network

Cui¹,

Mharakurwa

Ndiaye³

et al. 2015

The American Journal of Tropical Medicine and Hygiene

266

223

View full text Add to dashboard Cite

show abstract

“…Pyrimethamine failure was not noted after the early mass-administration trials in Venezuela [6], but in vitro antifolate resistance was demonstrated in malaria strains from Brazil in the mid-1960s [14] and Venezuela in the 1970s [15]. Where reported, SP remained effective in treating chloroquine-resistant infections until the 1980s [16]. In 1981, low-level (RI [17]) in vivo SP resistance was identified in the Colombian Amazon [10].…”

mentioning

confidence: 97%

Origin and Dissemination ofPlasmodium falciparumDrug‐Resistance Mutations in South America

Caraballo²,

et al. 2002

View full text Add to dashboard Cite

Multidrug resistance is a major obstacle to the control of Plasmodium falciparum malaria, and its origins and modes of dissemination are imperfectly understood. In this study, haplotyping and microsatellite analysis of malaria from 5 regions of the South American Amazon support the conclusion that the parasite mutations conferring mid- and high-level resistance to the antifolate combination sulfadoxine-pyrimethamine have a common origin. Parasites harboring these mutations are also found to share drug-resistance alleles that confer a unique chloroquine resistance phenotype and to be similar at loci not linked to drug resistance, although not genetically identical. Since the 1980s, multidrug-resistant P. falciparum has spread in a north-northwest manner across the continent, from an origin likely in the lower Amazon. This study highlights the importance of continent-wide malaria-control policies and suggests that the containment of resistance to the next generation of therapies may be feasible.

show abstract

“…Desde 1961 tem-se conhecimento da existência de cepas de Plasmodium falciparum resistentes às cloroquinas na Amazônia brasileira 17 , o que, posteriormente, tem sido confirmado por outros pesquisadores 5,7,8,15 A existência de cepas de Plasmodium falciparum resistentes à pirimetamina e sulfadoxina também tem sido descritas no Brasil 1,6 . Todavia, não há referências da existência de cepas amazônicas de Plasmodium falciparum resistentes à quinina e tetraciclina.…”

Section: Descrição Do Casounclassified

Resistência do Plasmodium falciparum ao fansidar, quinina e tetraciclina

1982

View full text Add to dashboard Cite

RESUMO: Descreve-se pela primeira vez uma cêpa amazônica de Plasmodium falciparum resistente ao Fansidar (pirimetamina mais sulfadoxina) e quinino mais tetraciclina simultaneamente. O paciente, com 13 anos de idade, residia há cinco anos em Ariquemes, Estado de Rondônia, na Amazônia brasileira. A infecção foi curada com dose elevada de cloroquina administrada em dose única intravenosa (IV). É evidenciado o alto valor da cloroquina na cura da malária falciparum resistente, quando administrada em doses maiores que as usadas nos esquemas convencionais de tratamento.

show abstract

Drug-Resistant Falciparum Malaria among the Mayongong Indians in the Brazilian Amazon *

Cited by 9 publications

References 0 publications

Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network

Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network

Origin and Dissemination ofPlasmodium falciparumDrug‐Resistance Mutations in South America

Resistência do Plasmodium falciparum ao fansidar, quinina e tetraciclina

Contact Info

Product

Resources

About